{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-089299","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.313428+00:00","generated_at":"2026-06-11T22:05:50.018016+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TELA Bio Q2 2023 revenue $14.5M (+39% YoY); reaffirms FY23 guidance $60-65M","bullets":["Q2 revenue $14.5M, up 39% YoY; H1 revenue $26.4M, up 42% YoY.","Gross margin improved to 70% vs 63% in Q2 2022 due to better inventory management.","Net loss $10.8M, narrower than $12.7M loss in prior-year quarter.","FY2023 revenue guidance reaffirmed: $60-65M, representing 45-57% growth.","Cash $65.3M after underwritten public offering netting ~$46.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-089299","json":"https://secwatch.observer/filing/0001104659-23-089299.json","markdown":"https://secwatch.observer/filing/0001104659-23-089299.md","text":"https://secwatch.observer/filing/0001104659-23-089299.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465923089299/0001104659-23-089299-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465923089299/tm2323228d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:05:50.018016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}